Plain-English translation of NCT06581315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a medication called can help prevent hepatocellular carcinoma (liver cancer) from coming back after surgery. Patients who have had surgery to remove high-risk liver tumors will either receive this medication for up to one year or be monitored carefully without the medication. The goal is to see if the treatment reduces the chance of cancer returning.
After surgery to remove liver cancer, there is a significant risk that the cancer will return—even when the surgery appears successful. Researchers want to know if giving this medication after surgery can lower that risk and help patients stay cancer-free longer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group will take the medication daily for up to one year or until the cancer returns, while the other group will have regular check-ups and scans to watch for any signs of cancer returning. Either way, you will have scheduled visits with your medical team to monitor your health, run blood tests, and do imaging scans to make sure the treatment is working and to catch any side effects early.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Enrollment target
~204 participants
Started
August 2024
Primary completion
August 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Changzhen Shang, MD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.